Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

Shinsuke Iida, Daisuke Ogiya, Yasunobu Abe, Masafumi Taniwaki, Hiroya Asou, Kaijiro Maeda, Kazunori Uenaka, Soshi Nagaoka, Tsuyoshi Ishiki, Ilaria Conti, Kensei Tobinai, Shinsuke Iida, Daisuke Ogiya, Yasunobu Abe, Masafumi Taniwaki, Hiroya Asou, Kaijiro Maeda, Kazunori Uenaka, Soshi Nagaoka, Tsuyoshi Ishiki, Ilaria Conti, Kensei Tobinai

Abstract

B-cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti-BAFF monoclonal antibody. This phase 1, multicenter, open-label, nonrandomized, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of tabalumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory MM (RRMM). Sixteen patients received intravenous i.v. tabalumab 100 mg (Cohort 1, n = 4) or i.v. tabalumab 300 mg (Cohort 2, n = 12) in combination with oral dexamethasone 20 mg/day and i.v. or s.c. bortezomib 1.3 mg/m(2) . All patients had treatment-emergent adverse events (TEAE) possibly related to study treatment; the most common TEAE were thrombocytopenia (81.3%), lymphopenia (43.8%) and increased alanine aminotransferase (43.8%). Two (20.0%) dose-limiting toxicities were observed, both in Cohort 2 (tabalumab 300 mg), which was below the predefined cutoff for tolerability (<33%). The pharmacokinetics of tabalumab were similar when bortezomib was coadministered i.v. versus s.c. The overall response rate was 56.3%, suggesting that the combined treatment was effective. In conclusion, combined treatment with these three agents was well tolerated in this population of Japanese patients with RRMM. The study was registered at www.clinicaltrials.gov (NCT01556438).

Keywords: Anti-B-cell activating factor monoclonal antibody; LY2127399; multiple myeloma; phase 1 study; tabalumab.

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Figures

Figure 1
Figure 1
Patient disposition. BTZ, bortezomib 1.3 mg/m2; DEX, dexamethasone 20 mg/day; IV, intravenous; LY, LY2127399 (tabalumab); SC, subcutaneous.
Figure 2
Figure 2
Mean ± SD serum LY2127399 (tabalumab) concentration–time profiles (linear) following intravenous infusion of LY2127399 (tabalumab) 100 or 300 mg in combination with i.v. or s.c. bortezomib 1.3 mg/m2 and oral dexamethasone 20 mg during Day 1 of Cycle 1 and Cycle 7. BTZ, bortezomib 1.3 mg/m2; DEX, dexamethasone 20 mg; IV, intravenous; LY, LY2127399 (tabalumab); SC, subcutaneous.
Figure 3
Figure 3
Mean plasma bortezomib concentration–time profiles (semi‐logarithmic) following intravenous infusion of LY2127399 (tabalumab) 100 or 300 mg in combination with i.v. or s.c. bortezomib 1.3 mg/m2 and oral dexamethasone 20 mg during Day 1 of Cycle 1. BTZ, bortezomib 1.3 mg/m2; DEX, dexamethasone 20 mg; IV, intravenous; LY, LY2127399 (tabalumab); SC, subcutaneous.
Figure 4
Figure 4
Relationship between baseline B‐cell activating factor (BAFF) levels and tumor response. Each data point represents an individual patient for responders (partial response or better: ●) and nonresponders (stable or progressive disease: Δ). For two patients, the response status was unknown.
Figure 5
Figure 5
Change in the immunoglobulins (Ig) A, G and M, and CD19+, IgD−, CD27+ (mature naïve B‐cell subset) over time for each patient in Cohort 1 (……..) and Cohort 2 (____). BTZ, bortezomib 1.3 mg/m2; DEX, dexamethasone 20 mg; IV, intravenous; LY, LY2127399 (tabalumab); SC, subcutaneous.

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–60.
    1. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population‐based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2011; 41: 139–47.
    1. Hengeveld PJ, Kersten MJ. B‐cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J 2015; 5: e282.
    1. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491–502.
    1. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172: 3268–79.
    1. Moreaux J, Legouffe E, Jourdan E et al BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148–57.
    1. Haiat S, Billard C, Quiney C, Ajchenbaum‐Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B‐cell chronic lymphocytic leukaemia. Immunology 2006; 118: 281–92.
    1. Tai YT, Li XF, Breitkreutz I et al Role of B‐cell‐activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675–82.
    1. Manetta J, Bina H, Ryan P, Fox N, Witcher DR, Kikly K. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane‐bound B‐cell activating factor. J Inflamm Res 2014; 7: 121–31.
    1. Neri P, Kumar S, Fulciniti MT et al Neutralizing B‐cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007; 13: 5903–9.
    1. Merrill JT, van Vollenhoven RF, Buyon JP et al Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B‐cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE‐2, a 52‐week, phase III, multicentre, randomised, double‐blind, placebo‐controlled study. Ann Rheum Dis 2016; 75: 332–40.
    1. Smolen JS, Weinblatt ME, van der Heijde D et al Efficacy and safety of tabalumab, an anti‐B‐cell‐activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double‐blind study. Ann Rheum Dis 2015; 74: 1567–70.
    1. Isenberg AD, Petri M, Kalunian K et al Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE‐1, a 52‐week, phase III, multicentre, randomised, double‐blind, placebo‐controlled study. Ann Rheum Dis 2016; 75: 323–31.
    1. Ocio EM, Richardson PG, Rajkumar SV et al New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525–42.
    1. Raje NS, Hohl RJ, Faber EA et al Phase I study of LY2127399, a human anti‐BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. J Clin Oncol 2011; 29: (suppl; abstr 8012).
    1. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008; 112: 159–68.
    1. Calhoun EA, Welshman EE, Chang CH et al Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group‐Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13: 741–8.
    1. Durie BG, Harousseau JL, Miguel JS et al International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–73.
    1. Millennium Pharmaceuticals . VELCADE (Bortezomib): Highlights of Prescribing Information. Cambridge, MA: Millennium Pharmaceuticals, 2014.
    1. Moreau P, Pylypenko H, Grosicki S et al Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non‐inferiority study. Lancet Oncol 2011; 12: 431–40.
    1. Abe M, Kido S, Hiasa M et al BAFF and APRIL as osteoclast‐derived survival factors for myeloma cells: a rationale for TACI‐Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313–5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe